Genesis HealthCare (GEN) Reports In-Line Q3 EPS ; Offers Guidance

Genesis HealthCare (NASDAQ: GEN) reported Q3 EPS of $0.47, in-line with the analyst estimate of $0.47. Revenue for the quarter came in at $948 million versus the consensus estimate of $945 million.

GUIDANCE:

Genesis HealthCare sees Q4 2023 EPS of $0.49-$0.51, versus the consensus of $0.51. Genesis HealthCare sees Q4 2023 revenue of $950-960 million, versus the consensus of $967.3 million.

Genesis HealthCare sees FY2023 EPS of $1.95-$2.00, versus the consensus of $1.98. Genesis HealthCare sees FY2023 revenue of $3.81-3.84 billion, versus the consensus of $3.83 billion.

For earnings history and earnings-related data on Genesis HealthCare (GEN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• Pfizer lung cancer drug misses survival goal in Phase 3 trial